<DOC>
	<DOCNO>NCT00392171</DOCNO>
	<brief_summary>The purpose non-randomized , open-label , multicenter , Phase II , 2-stage design , RESCUE study test hypothesis continuous 28-day oral dosing ( 28/28 ) dose-intense temozolomide ( 50 mg/m^2 ) 12 month may overcome resistance effective management adult patient malignant glioma fail follow least 2 cycle ( 2 month ) conventional 5-day ( 5/28 ) cycle high-dose temozolomide ( 150-200 mg/m^2 ) .</brief_summary>
	<brief_title>The Effects Continuous 28-day ( 28/28 ) Temozolomide Chemotherapy Subjects With Recurrent Malignant Glioma Who Have Failed Conventional 5-day ( 5/28 ) Treatment ( P04601AM1 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Adult patient , great 18 year old . Surgically confirm diagnosis malignant glioma , specifically anaplastic glioma ( anaplastic astrocytoma [ AA ] , anaplastic oligodendroglioma [ AO ] , anaplastic oligoastrocytoma [ AOA ] ) glioblastoma multiforme ( GBM ) . Must complete least 2 cycle ( 2 month ) conventional 5/28 temozolomide , radiological evidence progression . GBM treat concurrent chemoradiation temozolomide accord EORTC/NCIC ( European Organization Research &amp; Treatment Cancer/National Cancer Institute Canada ) protocol . Evidence progression confirm radiologically ( CT [ compute tomography ] MRI [ magnetic resonance image ] ) . Patients must enrol within 2 week last radiological confirmation progression , except patient undergo surgical resection . Patients undergo surgical resection recurrent disease must enrol within 2 week postsurgical scan . Patients residual disease surgery allow . Steroids dose stabilize last 2 week prior enrollment . Use medically approve contraception fertile male female . Women childbearing potential must negative urine serum pregnancy test ( urinary excretion serum level bHCG [ beta human chorionic gonadotropin ] ) within 24 hour inclusion study . Eastern Cooperative Oncology Group ( ECOG ) score 0 1 . Signed informed consent form . GBM progression first 2 month adjuvant temozolomide ( 5/28 ) . AA progression first 2 month standard temozolomide therapy ( 5/28 ) . Chemotherapy malignant glioma temozolomide . More one prior course chemotherapy temozolomide . Patient evolve anaplastic glioma GBM follow primary therapy . Patient old 70 year receive conventional chemoradiation regimen . Patient receive radiotherapy recurrent disease . Patient metastatic disease . Known human immunodeficiency virus ( HIV ) infection . History noncompliance therapy . Inadequate hematological , renal hepatic function accord follow laboratory value ( perform within 14 day , inclusive , prior study inclusion ) : Absolute neutrophil count &lt; =1.5 ×10^9/L ; Platelets &lt; =100 ×10^9/L ; Hemoglobin &lt; 90 g/L ; Serum creatinine &gt; =1.5 time upper limit laboratory normal ( ULN ) ; Total serum bilirubin &gt; =1.5 time ULN ; ASAT ( AST [ aspartate aminotransferase ] ) ALAT ( ALT [ alanine aminotransferase ) &gt; 2.0 time ULN ; Alkaline phosphatase &gt; 2.5 time ULN . Known chronic hepatitis B hepatitis C infection . Any serious medical condition , accord medical judgment physician prior inclusion study . Any medical condition could interfere oral medication intake ( e.g. , frequent vomiting , partial bowel obstruction ) . Other malignancy previous 5 year exception surgically cure carcinoma insitu cervix basal cell carcinoma nonmelanoma skin cancer . Any psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule discuss patient inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>